StudyFinder
Search Results
1 Study Matches
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tables for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)
Prurigo Nodularis: Phase 2b/3 Subject and Investigator Blinded, 56 Week study. Oral medication taken twice daily, Males/Females 18 years and older with Prurigo Nodularis Prurigo Nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, cause people to scratch themselves to the point of bleeding or pain. The goal of this study is to evaluate the change of itch with using Nalbuphine ER.
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT03497975
STUDY00012668
Inclusion Criteria:
PN involving 2 affected areasWilling to follow all study directions and attend appointments
Exclusion Criteria:
PN affecting only 1 part of the bodyCertain diagnosis associated with PN are not allowed, coordinator will discuss specifics
Skin Conditions